Autologous transplantation therapy for chronic myelogenous leukemia

Blood

Volumn 89, Issue 8, 1997, Pages 2623-2634

  Bhatia, Ravi ^a   Verfaillie, Catherine M ^a   Miller, Jeffrey S ^a   McGlave, Philip B ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; ALPHA INTERFERON; AMSACRINE; BCR ABL PROTEIN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; HLA DR ANTIGEN; HYDROXYUREA; IDARUBICIN; MAFOSFAMIDE; MITOXANTRONE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA INTERFERON;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; CANCER SURVIVAL; CHROMOSOME 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW;

EID: 0030902062     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.2623     Document Type: Review

References (103)

1. Nowell PC, Hungerford DA: A minute chromosome in human chronic granulaocytic leukemia. Science 132:1497, 1960
2. Rowley JD: A new consistent chromosome abnormality in chronic myelogenous leukemia: Nature 243:209, 1973
3. DeKlein A, Van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bostooma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765, 1982
4. Daley GQ, Baltimore D: Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic leukemia-specific P210 bcr/abl protein. Proc Natl Acad Sci USA 85:9312, 1988
5. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science 247:824, 1990
6. Clift R, Appelbaum F, Thomas E: Bone marrow transplantation for chronic myelogenous leukemia. Blood 83:2752, 1994
7. McGlave P, Bartsch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan N: Unrelated marrow transplantation for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program. Blood 81:543, 1993
8. Petersdorf EW, Smith AG, Mickelson EM, Longton GM, Anasetti C, Yoon Choo S, Martin PJ, Hanson JA: The role of HLA-DPB1 disparity in the development of acute graft-versus-host disease following donor marrow transplantation. Blood 81:1923, 1993
9. Nadamanee A, Schmidt GM, Parker P, Dagis AC, Stein A, Snyder DS, O'Donnell M, Smith EP, Stepan DE, Molina A, Wong KK, Margolin K, Somlo G, Littrell B, Woo D, Sniecinski I, Niland JC, Forman SJ: The outcome of matched unrelated donor bone marrow transplantation in patients with hematological malignancies using molecular typing for donor selection and graft-vs-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone. Blood 86:1228, 1995
10. Korbling M, Przepiorka D, Huh YO, Elfenbien G, Santos G, Kaizer H: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma - Potential advantage of blood over marrow allografts. Blood 85:1659, 1995
11. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE: Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 346:214, 1995
12. van Rhee F, Lin F, Cross NCP, Reid CDL, Lakhani AKV, Szydlo RM, Goldman JM: Detection of residual leukemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Bone Marrow Transplant 14:609, 1994
13. Goldman J, Gale R, Horowitz M, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
14. Enright H, Daniels K, Arthur DC, Dusenberry KE, Kersey JH, Kim T, Miller WJ, Ramsay NKC, Vercellotti GM, Weisdorf DJ, McGlave PB: Related donor marrow transplant for chronic myelogenous leukemia: Patient characteristics predictive of outcome. Bone Marrow Transplant. 17:537, 1996
15. Giralt S, Champlin RE: Leukemia relapse after allogeneic marrow transplantation: A review. Blood 84:3603, 1994
16. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M: Treatment of chronic myelogenous leukemia: Current status and investigational options. Blood 87:3069, 1996
17. Mahon F, Montastruc M, Faberes C, Reiffers J: Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-α. Blood 84:3592, 1994
18. Ohnishi K, Ohno R, Tomonaga M, Tamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 89:906, 1995
19. Ozer H, George S, Schiffer C, Rao K, Rao PN, Wuster-Hill DH, Arther DD, Powell B, Gottlieb A, Peterson BA, Rai K, Testa JR, LeBeau M, Tantravahi R, Bloomfield CD: Prolonged subcutaneous administration of recombinant alfa-2b interferon in patients with previously untreated Philadelphia-chromosome positive chronic-phase chronic myelogenous leukemia: Effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975, 1993
20. Allan N, Richards S, Shepard P: UK Medical Research Council randomized multicenter trial of interferon-α in chronic myelogenous leukemia-improved survival irrespective of cytogenetic response. Lancet 345:1392, 1995
21. Hehlman R and the German CML Study Group: Randomized comparison of interferon-α with busulphan and hydroxyurea in chronic myelogenous leukemia. Blood 84:4064, 1994
22. The Italian Cooperative Study Group on Chronic Myelogenous Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myelogenous leukemia. N Engl J Med 330:820, 1994
23. Dhingra K, Kurzrock R, Baine R, Eastman S, Kantarjian H, Gutterman JU, Talpaz M: Minimal residual disease in interferon-treated chronic myelogenous leukemia: Results and pitfalls of analysis based on polymerase chain reaction. Leukemia 6:754, 1992
24. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R: Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J Clin Invest 94:1383, 1994
25. 1 negative cells in bone marrow and a ten year remission after Busulphan hypoplasia. Br J Haematol 23:283, 1972
26. Cunningham I, Gee T, Dowling M, Chaganti R, Bailey R, Hopfan S, Bowden L, Turnbull A, Knapper W, Clarkson B: Results of treatment of Ph1 positive chronic myeloid leukemia with an intensive treatment regimen (L-5 protocol). Blood 53:375, 1979
27. + chronic myelogenous leukemia in vivo and in vitro and effects of intensive treatment with the L-15 protocol. Blood 59:793, 1982
28. Smalley RV, Vogel J, Huguley CM Jr, Miller D: Chronic granulocytic leukemia: Cytogenetic conversion of the bone marrow with cycle-specific chemotherapy. Blood 50:107, 1977
29. Buckner CD, Stewart P, Clift RA, Fefer A, Neiman PE, Singer J, Storb R, Thomas ED: Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 6:96, 1978
30. Talpaz M, Kantarjian HM, Kurzrock R, Trujillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosone positive patients. Ann Intern Med 114:532, 1991
31. Chervenick PA, Ellis LD, Pan SF, Lawson AL: Human leukemic cells: In vitro growth of colonies containing the Philadelphia (Ph) chromosome. Science 174:1134, 1971
32. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC: Long term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 306:1493, 1983
33. Hogge DE, Coulombel L, Kalousek DK, Eaves CJ, Eaves AC: Nonclonal hematopoietic progenitors in a G6PD hetrerozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 24:389, 1987
34. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992
35. Leemhuis T, Leibowitz D, Cox G, Silver R, Srour EF, Tricot G, Hoffman R: Identification of blast crisisR/ABL-negative primitive hematopoietic progenitor cells within chronic myelogenous leukemia marrow. Blood 81:801, 1993
36. lo population in chronic myelogenous leukemia: An analysis using interphase fluorescence in situ hybridization. Blood 86:737, 1995
37. Haines ME, Goldman JM, Worsely AM, McCarthy DM, Wyatt SE, Dowding C, Kearney L, Th'ng KH, Wareham NJ, Pollock A, Galvin MC, Samson D, Geary CG, Catovsky D, Galton DAG: Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: Probable prolongation of survival for some patients. Br J Haematol 58:711, 1984
38. Reiffers J, Troutte R, Marit G, Montastruc M, Faberes C, Cony-Makhoul P, David B, Bordeau MJ, Bilhou-Nabera C, Lacombe F, Feuillatre-Fabre F, Vezon G, Bernard PH, Broustet A: Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: A report of 47 cases. Br J Haematol 77:339, 1991
39. Hoyle C, Gray R, Goldman J: Autografting for patients with CML in chronic phase: An update. Br J Hematol 86:76, 1994
40. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A: Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 14:407, 1994
41. Degliantoni G, Mangoni N, Rizzoli V: In vitro restoration of polyclonal hematopoiesis in a chronic myelogenous leukemia after in vitro treatment with 4-hydroperoxycyclophoshamide. Blood 65:753, 1985
42. Carlo-Stella C, Mangoni L, Almici C, Caramatti C, Cottafavi L, Dotti GP, Rizzoli V: Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 14:425, 1994
43. McGlave P, Miller J, Miller W, Perry E, Fautsch S, Ramsay NKC, Verfaillie CM, Weisdorf DW: Autologous marrow transplant therapy for CML using marrow treated ex vivo with human recombinant interferon gamma. Blood 84:537, 1994 (abstr, suppl 1)
44. Barnett MJ, Eaves CJ, Phillips GL, Gascoyne RD, Hogge DE, Horsman DE, Humphries RK, Klingeman H-G, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Spinelli JG, Sutherland HJ, Eaves AC: Autografting with cultured marrow in chronic myelogenous leukemia: Results of a pilot study. Blood 84:724, 1994
45. Brion A, Charbord P, Flesch M, Deconinck E, Deschaseux M, Racadot EW, Cahn JY: Autografting with cultured marrow in CML: Problem of hematopoietic reconstitution. Bone Marrow Transplant 15:S22, 1995
46. Korbling M, Burke P, Braine H, Elfenbien G, Santos G, Kaizer H: Successful engraftment of blood derived stem cells in chronic myelogenous leukemia. Exp Hematol 9:684, 1981
47. Carella AM, Frassoni F, Podesta M, Pungolino E, Pollicardo N, Ferrero R, Soracco M: Idarubicin containing regimen and G-CSF are able to recruit a high rate of normal progenitor cells during early hematopoietic recovery in patients with CML. J Hematother 3:199, 1994
48. Carella AM, Frassoni F, Negrin RS: Autografting in chronic myelogenous leukemia: New questions. Leukemia 9:365, 1995
49. Talpaz M, Kantarjian H, Liang J, Calver M, Hamer J, Tibbits P, Durett A, Claxton D, Giralt S, Khouri I, Przepiorka D, van Besien K, Anderson B, Mehra R, Gajewski J, Seong D, Hester J, Estey E, Korbling M, Pollicardo N, Berenson R, Heimfield S, Champlin R, Desseroth AB: Percentage of Philadelphia chromosome (Ph)-negative and Ph Positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells. Blood 85:3257, 1995
50. Tringali S, Santoro A, Scimi R, Vasta S, Pampinella M, Marino MA, Majolino I: High-dose cyclophosphamide for mobilization of circulating stem cells in chronic myelogenous leukemia. Eur J Haematol 53:1, 1994
51. O'Brien SG, Rule S, Spencer A, Savage D, Apperly J, Chase AJ, Mconald C, Davidson RJ, Goldman JM: Autografting in chronic phase CML using PBPCs mobilized by intermediate-dose chemotherapy. Bone Marrow Transplant 15:S11, 1995
52. Chalmers EA, Franklin IM, Kelsey S, Clarke R, Sproul AM, Goldstone AH, Hepplestone A, Watson W, Sharp S, Tansey P: Mobilization of Ph negative progenitors into peripheral blood in chronic myelogenous leukemia (CML) using ldarubicin and Cytarabine. Blood 84:400a, 1994 (abstr, suppl 1)
53. Durrant S, Taylor K, Moore D, Hutchins C, Eliadis P, Grigg A, Atkinson K: Bone marrow transplant following intensive chemotherapy with filgrastim support and progenitor cell collection in advanced chronic myelogenous leukemia. Bone Marrow Transplant 15:S19, 1995
54. Sureda A, Brunet S, Amill B, Aventin A, Sanchez JA, Mateu R, Portos JM, Madoz P, Gomez de Segura G, Garcia Lopez J, Domingo-Albos A: Peripheral blood stem cell mobilization in patients with chronic myelogenous leukemia. Bone Marrow Transplant 15:S20, 1995
55. Simonsson B, Oberg G, Killander A, Bjoreman M, Borkholm M, Gahrton G, Hast R, Turreson I, Uden AM, Malm C, Vilen L, Wahlin A, Lofvenberg E, Carnescog J, Westin J: Intensive treatment in order to minimize the Ph negative/positive clone in chronic myelogenous leukemia. Stem Cells 111:73, 1993 (suppl 3)
56. McGlave PB, De Fabritiis P, Deisseroth A, Goldman J, Barnett M, Reiffers J, Siminsson B, Carella A, Aeppli D: Autologous transplants for chronic myelogenous leukemia: Results from eight transplant groups. Lancet 343:1486, 1994
57. Etkin M, Filaccio M, Ellerson D, Suh S-P, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Moseley AM, Reading C, Khouri I, Talpaz M, Kantarjian H, Deisseroth A: Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther 3:137, 1992
58. Deisseroth AB, Zhifei Zu, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, French Anderson W, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfield S, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C: Genetic marking shows that Ph positive cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068, 1994
59. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079, 1990
60. McWhirter JR, Wang JYJ: An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 12:1533, 1993
61. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguernara L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562, 1991
62. 1 leukemia growth in mice by bcr-abl antisense oligonucleotides. Proc Natl Acad Sci USA 91:4504, 1994
63. de Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B: In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematological reconstitution after autologous bone marrow transplantation. Leukemia 9:662, 1995
64. Wagner RW: Gene inhibition using antisense oligodeoxynucleotides. Nature 372:333, 1994
65. Keating A, Wang XN, Laraya P: Variable transcription of bcr-abl by Ph positive cells arising from hematopoietic progenitors in chronic myelogenous leukemia. Blood 83:1744, 1994
66. Skorski T, Nieberowska-Skorska M, Barletta C, Malaguernara L, Szczylik C, Chen S-T, Lange B, Calabretta B: Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with Mafosfamide. J Clin Invest 92:194, 1992
67. Zhao R, Mcivor S, Verfaillie CM: Development of a retroviral gene transfer strategy that may improve disease free survival after autografting in CML. Blood 86:245a, 1996 (abstr, suppl 1)
68. Shore SK, Nabissa PM, Reddy EP: Ribozyme-mediated cleavage of the bcr-abl oncogene transcript: In vitro cleavage of RNA and in vivo loss of p210 protein kinase activity. Oncogene 8:3183, 1993
69. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome positive cell line. Blood 82:600, 1993
70. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy EP: Multi-unit ribozyme-mediatedcleavage of bcr-abl mRNA in myeloid leukemias. Blood 85:2162, 1995
71. Calabretta B, Sims RB, Valiteri M, Caracciolo D, Szczylik C, Venturelli D, Rtajczak M, Beran M, Gewirtz AM: Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligonucleotides: An in vitro sudy relevant to bone marrow purging. Proc Natl Acad Sci USA 88:2351, 1991
72. Luger SM, Ratjczak MZ, Stadtmauer EA, Mangan P, Magee D, Silberstein L, Edelstein M, Nowell P, Gewirtz AM: Autografting for chronic myelogenous leukemia with c-myb antisense oligonucleotide purged bone marrow: A preliminary report. Blood 84: 151a, 1994 (abstr, suppl 1)
73. Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, Kurosawa M, Miyazaki T: Effect of herbimycin A, an antagonist of tyrosine kinase on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition of Ph1-positive leukemia cell growth. Blood 80:1330, 1992
74. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA: Tyrphostin induced growth inhibition: Correlation with effect on p210bcr/abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs 5:213, 1994
75. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB: Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 2:561, 1996
76. Verfaillie C, Blakholmer K, McGlave P: Purified primitive human hematopoietic progenitors with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma. J Exp Med 179:509, 1990
77. - phenotype in early chronic phase (ECP) but not advanced phase (AP) CML. Blood 87:4770, 1996
78. Bhatia R, McGlave PB, Lin W, Wissink S, Miller JS, McGlave PB: Ex vivo expansion of LTC-IC and CFC is possible in a clinically suitable stroma conditioned medium culture supplemented with one or two cytokines. Blood 86:1163a, 1995 (abstr, suppl 1)
79. Verma UN, Bagg A, Brown E, Mazumder A: Interleukin-2 activation of human bone marrow in long-term cultures: An effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13:115, 1994
80. Verfaillie C, Miller W, Kay N, McGlave P: Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: A benign cell population with potent cytotoxic activity. Blood 74:793, 1989
81. Verfaillie C, Kay N, Miller W, McGlave P: Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood 76:401, 1990
82. Miller JS, Verfaillie C, McGlave PB: Expansion and activation of human natural killer cells as therapy for autologous transplantation. Prog Clin Biol Res 389:39, 1994
83. Cervantes F, McGlave PB, Miller JS: Autologous activated natural killer cells (ANK) suppress CML progenitors but spare normal hematopoiesis in long term bone marrow cultures (LTC). Blood 87:2476, 1996
84. Bhatia R, McGlave PB: T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors. Leukemia 9:1006, 1995
85. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587, 1996
86. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF: Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328:342, 1987
87. Verfaillie CM, McCarthy JB, McGlave PB: Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia: Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type TV. J Clin Invest 90:1232, 1992
88. Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA: The COOH terminus of the c-ABL tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity. J Cell Biol 124:325, 1994
89. McWhirter JR, Wang JYJ: Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 11:1553, 1991
90. Bhatia R, Verfaillie CM: Inhibition of BCR-ABL expression by antisense oligonucleotides normalizes β1 integrin mediated adhesion and regulation of proliferation in chronic myelogenous leukemia. Blood 86:1740a, 1995 (abstr, suppl 1)
91. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves AC: Unregulated proliferation of primitive chronic myelogenous leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 83:5306, 1986
92. Bhatia R, McCarthy JB, Verfaillie CM: Interferon-α restores normal negative regulation of CML progenitor proliferation by the marrow microenvironment by restoring normal β1 integrin mediated proliferation inhibition. Blood 87:3883, 1996
93. Eaves CJ, Cashman JD, Wolpe SD, Eaves AC: Unresponsiveness of primitive chronic myelogenous leukemia cells to macrophage inflammatory protein 1α, an inhibitor of primitive normal cells. Proc Natl Acad Sci USA 90:12015, 1993
94. Agarwal R, Doren S, Hicks B, Dunbar CE: Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 85:1306, 1995
95. Horowitz M, Gale R, Sondel M, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
96. Gale RP, Champlin R: How does bone marrow transplantation cure leukemia? Lancet 2:28, 1984
97. Higano CS, Raskind WH, Singer JW: Use of α-interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 80:1437, 1992
98. Browett PJ, Nelson J, Tiwari S, Van de Water NS, May S, Palmer SJ: Graft-versus-host disease following interferon therapy for relapsed chronic myelogenous leukemia post-allogeneic bone marrow transplantation. Bone Marrow Transplant 14:641, 1994
99. Pigneux A, Devergie A, Pochitaloff M, Archimbaud E, Cahn JV, Leblond V, Michallet M, Jouet JP, Guilhot F, Gluckman B, Reiffers J: Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: A report from the Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 15:819, 1995
100. Weisdorf DJ, Anderson PM, Blazar BR, Uckun FM, Kersey JH, Ramsay NKC: Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia - A phase I study. Transplantation 55:61, 1993
101. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplant 16:283, 1995
102. Rowe J, Ryan D, Dipersio J, Nilsson B, Larsson L, Liesveld J, Kouides P, Simonsson B: Autografting in chronic myelogenous leukemia followed by immunotherapy. Stem Cells 11:34, 1993 (suppl 3)
103. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M, Leitman S, Gottesman M, Pastan I, Denicoff A, Noone M, Gress R: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5:891, 1994